F32.0 F32.1 F33.0 F33.1 F38.1 F38.8 F41.2 F43.2
Conditions
Interventions
Group 1: VISION-AGE is a standardised, age-sensitive group psychotherapy programme, carried out via video conference by trained psychotherapists. Well-established life-review therapy methods are enric
Sponsors
MSB Research, Development and Innovation gGmbH (MSB-RDI)
Eligibility
Sex/Gender
All
Age
68 Years to No maximum
Inclusion criteria
Inclusion criteria: • the person has the capacity to give informed consent, voluntarily agree to participate in the study • they are diagnosed with mild or moderate unipolar depressive symptoms associated with one of the following ICD-10 diagnoses: F32.0/1, F33.0/1, F38.1/8, F41.2 or F43.2 based on a clinical interview • they have clinically relevant depressive symptoms based on self-report • they are not taking psychoactive medications or are taking a stable dosage for at least six weeks prior to study entry • they have an indication for participation in group psychotherapy • sufficient language and communication skills in German • functioning, stable internet connection and basic IT skills
Exclusion criteria
Exclusion criteria: • very severe depressive symptoms associated with one of the following ICD-10 diagnoses F32.2 or F33.2 based on the clinical interview • very severe depressive symptoms based on the self-report • very severe anxiety symptoms or symptoms of panic disorder or specific phobia that mandate in vivo exposure • acute suicidal tendencies • signs of or they have been diagnosed with dementia or mild cognitive impairment • signs of or they have been diagnosed with bipolar disorder or schizophrenia • physical illness in the terminal phase • plan to change their intake of psychoactive medications before enrolment or during the study • receiving psychotherapy while participating in the study • communication difficulties and visual or hearing impairments that would severely affect an individual’s ability to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome variable is the reduction in participants' depressive symptoms, as indicated by changes in their self-reported scores on the Patient Health Questionnaire-9 (PHQ-9) between pre- and post-treatment and follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| As secondary outcomes, changes from baseline measurement to posttreatment and follow-up will be examined in the following concepts: • clinician-rated depressive symptoms (Montgomery-Åsberg Depression Rating Scale, MADRS) • anxiety symptoms (Geriatric Anxiety Scale, GAS) • psychological well-being (short version of the the Ryff, SPWB) The following concepts of self- and developmental regulation will be assessed as mediator variables at baseline, at one of the four intermediate time points, after the completion of the respective module, at post-treatment, and at follow-up: • Positive self-perceptions of ageing, fostered in Module 1, is operationalised as the inverse of the score on the self-directed ageism subscale of the World Health Organisation (WHO) Ageism Scale (translated into German by the research team and expanded by four items) • Reminiscence, fostered in Module 2, will be assessed as ego-integrity by using short version of the Northwestern Ego Integrity Scale (NEIS; translated into German by the research team) • Life management, fostered in Module 3, will be assessed using the Scale Selection Optimisation Compensation (SOC) • Future planning, fostered in Module 4, will be assessed using a modified 6-item version of the Preparation for Future Care Needs – 5-item short scale (PFC; translated into German and modified by the research team). | — |
Countries
Germany
Contacts
Public ContactEva-Marie Kessler
MSB Medical School Berlin
Outcome results
None listed